Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18090623 | 1.00 | LMNA (0.38) | LMNAMAPK1HTTHRH1CYP1A2 | |
| SCHEMBL13890695 | 0.91 | CYP1A2 (0.40) | LMNAMAPK1HTTHRH1CYP1A2 | |
| SCHEMBL29187201 | 0.91 | HRH1 (0.38) | LMNAMAPK1HTTHRH1CYP1A2 | |
| SCHEMBL79852 | 0.87 | — | — | |
| SCHEMBL1543625 | 0.87 | CYP1A2 (0.38) | LMNAMAPK1HTTCYP1A2ESR2 | |
| SCHEMBL13223460 | 0.84 | ESR2 (0.42) | LMNAMAPK1HTTHRH1ESR2 | |
| SCHEMBL2702409 | 0.84 | ESR2 (0.42) | LMNAMAPK1HTTHRH1ESR2 | |
| SCHEMBL17429992 | 0.84 | ESR2 (0.42) | LMNAMAPK1HTTHRH1ESR2 | |
| SCHEMBL18421585 | 0.81 | ESR2 (0.43) | LMNAMAPK1HTTCYP1A2ESR2 | |
| SCHEMBL18421980 | 0.81 | SIGMAR1 (0.37) | LMNAMAPK1HTTCYP1A2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124551-A1 | RHODAMINE-BASED COLORING COMPOSITION | Wako Pure Chemical Industries, Ltd. (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-8580146-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20120193577-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| WO-2007092681-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1077953-A2 | BISOXIMETHER DERIVATIVES, METHODS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF, AND THEIR USE FOR COMBATING FUNGICIDAL PESTS AND ANIMAL PESTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059982-A2 | BISOXIMETHER DERIVATIVES, INTERMEDIATE PRODUCTS, AND THEIR USE FOR COMBATING FUNGICIDAL PESTS AND ANIMAL PESTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120193577-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, MARK3, CCND3 | LMNA 1961/4885MAPK1 1123/4885HTT 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.